ClinicalTrials.gg
TerminatedNCT01939223COASTUpdated Oct 20, 2017Results posted

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

A Phase 3 interventional study of Regorafenib (Stivarga, BAY73-4506) and Placebo in Colorectal Neoplasms, sponsored by Bayer. Terminated at 121 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-20.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
45th of 58
25 · median 55
Started
2013
with 6 others
Phase 3
7 of 59
1 open now
Registered
10th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 45th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2013, is one of 7 in phase 3, and was the 10th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy.

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • Stage IV colorectal cancer / Liver Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a history of a primary adenocarcinoma of the colon and / or rectum
  • Have a history of Stage IV Colorectal Cancer (CRC) with to the liver only
  • Have received at least 3 months ,of , adjuvant, or perioperative chemotherapy, including a fluoropyrimidine and either oxaliplatin or irinotecan or both for subjects with initial Stage IV CRC which were treated with surgery with curative intent for both primary and metastatic lesions. The total chemotherapy administered, including that administered prior to and after liver resection, should not exceed 9 months. OR Have received surgery with curative intent for primary CRC and at least 3 months ,of neoadjuvant, adjuvant, or perioperative chemotherapy for the primary tumor, including a fluoropyrimidine or a fluoropyrimidine and either oxaliplatin or irinotecan or both

    • For subjects with liver metastases developing > 6 months after completing treatment for primary CRC and having undergone surgery with curative intent for liver metastases, a second course of chemotherapy lasting at least 3 months needs to be administered, including a fluoropyrimidine and either oxaliplatin or irinotecan or both. The second course of chemotherapy should not exceed 9 months.
  • For subjects who developed liver metastases >/=6 months after completing treatment for primary CRC and having undergone surgery with curative intent for liver metastases, a second course of chemotherapy is not permitted unless initial adjuvant therapy consisted of fluoropyrimidine monotherapy. Subjects who received fluoropyrimidine alone must have received a second course of chemotherapy with fluoropyrimidine and either oxaliplatin or irinotecan or both, which should not exceed 9 months.For subjects with initial Stage I or II disease, no chemotherapy is required for a primary CRC lesion treated with surgery with curative intent. These subjects must receive chemotherapy for the treatment of liver metastases (which were also treated with surgery with curative intent), which must last at least 3 months, including a fluoropyrimidine and either oxaliplatin or irinotecan or both. The total course of chemotherapy should not exceed 9 months.
  • Prior to randomization, have histological confirmation that CRC lesions were adenocarcinoma (subtypes of adenocarcinoma, e.g. mucinous adenocarcinoma are allowed). Subjects with CRC lesions of other histological types, including mixed type with predominant adenocarcinoma, will not be eligible to be randomized to study treatment.
  • Have pathology-proven complete removal of all primary and liver metastatic CRC lesions. Subjects with positive margins will not be eligible for the study.
  • Have adequate bone marrow function, liver function, and renal function, as measured by the following laboratory assessments conducted within 7 days prior to the initiation of study treatment:

    • Total \</=1.5 times the (ULN)
    • and aspartate aminotransferase \</= 3 times the ULN
    • Lipase\</=1.5 times the ULN
    • Serum creatinine\</=1.5 times the ULN
    • Carcinoembryonic antigen (CEA)\</=3 times the ULN
    • >/=30 mL/min/1.73 m2 according to the Modified Diet in Renal Disease abbreviated formula
    • of prothrombin time and activated partial thromboplastic time \</=1.5 times the ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no underlying abnormality in coagulation parameters exists per medical history.
    • count >/=100,000 /mm3, >/=9 g/dL, >/= 1500/mm3 without transfusions or granulocyte colony stimulating factor and other hematopoietic growth factors
    • Alkaline phosphatase ≤ 2.5 times the ULN
  • Have had a CT or MRI scan (chest, abdomen, pelvis and other suspected sites as applicable) to determine eligibility for randomization within 4 weeks prior to randomization (hereafter referred to as the "eligibility scan")
  • Have an (ECOG) performance status of 0 or 1 within 14 days prior to the initiation of study treatment
  • If female and of , or if male, agree to use adequate (e.g., abstinence, intrauterine device, oral contraceptive, or double barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until 8 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Are taking strong cytochrome P (CYP) inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort).
  • Have used biologic response modifiers, such as granulocyte-colony stimulating factor, within 3 weeks prior to signing the ICF.
  • Have had prior treatment with regorafenib or any other (vascular endothelial growth factor receptor) VEGFR-targeting kinase inhibitor.
  • Have had anti-cancer treatment following liver resection that exceeded a duration of 6 months.
  • Have been treated with biologics (eg, antibodies targeting VEGFR or EGFR) after liver resection unless the administration of the biologic started prior to liver resection and continued after liver resection only to complete a pre-specified number of cycles.
  • Completed their last dose of chemotherapy or had their last cancer surgery more than 10 weeks, whichever came later, prior to randomization.
  • Have extra-hepatic disease. Suspicious lesions should be rigorously evaluated with other imaging techniques and/or to exclude extra-hepatic metastatic disease prior to submitting for central radiology review.
  • Have had systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation of study treatment.
  • Are pregnant and or breast feeding.
  • Have had prior or concurrent cancer distinct in primary site or histology from CRC within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer, Stage 0 intramucosal gastric cancer after endoscopic complete removal, or superficial bladder tumors classified as noninvasive tumor (Ta), carcinoma in situ (Tis), or tumor invades lamina propria (T1).
  • Have congestive heart failure classified as Class 2 or higher.Have had unstable angina (angina symptoms at rest) or new-onset angina ≤ 3 months prior to screening. Have had a myocardial infarction \< 6 months prior to initiation of study treatment.
  • Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin.
  • Have uncontrolled hypertension (systolic blood pressure [SBP] greater than140 mmHg or diastolic blood pressure [DBP] greater than 90 mmHg) despite optimal medical management.
  • Have pheochromocytoma.
  • Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis, or pulmonary embolism within 6 months prior to the initiation of study treatment.
  • Have a known history of infection.
  • Have either active or chronic or C requiring treatment with antiviral therapy.
  • Have a seizure disorder requiring medication.
  • Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity.
  • Have had a hemorrhage or a bleeding event >/=Grade 3 ( v 4.0) within 4 weeks prior to the initiation of study treatment.
  • Have any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Regorafenib

    4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.

    Drug: Regorafenib (Stivarga, BAY73-4506)

  • Placebo comparator
    Placebo

    4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.

    Drug: Placebo

Interventions

  • Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment

  • DrugPlacebo

    Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment

06

What researchers measure

Primary outcomes

  1. Disease Free Survival (DFS) as Assessed by the Investigator

    Disease free survival was evaluated by CT / MRI scans as assessed by the investigator, which was defined as the time (in days) from date of randomization to date of first observed radiographic disease recurrence (RECIST 1.1 criteria for measurable and non-measurable disease) or death due to any cause, if death occurred before disease recurrence was documented. For subjects without documented disease recurrence or death at the time of analysis, the DFS time was censored at the date of the last evaluable CT / MRI scan.

    Time frame: From date of randomization to date of first observed radiographic disease recurrence (RECIST 1.1 criteria for measurable and non-measurable disease) or death due to any cause, if death occurred before disease recurrence was documented.

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) is defined as the time (days) from randomization to death due to any cause. The OS time for subjects alive at the time of analysis was censored at their last date known to be alive.

    Time frame: Subjects who experienced disease recurrence (either during treatment or during Active Follow-up), or otherwise withdrew from the study for any reason other than death, were followed for overall survival unless consent was withdrawn.

07

Results

Posted Oct 20, 2017
Limitations and caveats
This study was prematurely terminated. Analysis was not performed for primary and secondary outcome measures.

Participant flow

This multinational study was conducted at 32 study centers that screened 65 subjects across 9 countries, between 02 December 2013 (start of enrollment) and 29 August 2016 (last patient last vist).

Participant flow — Overall Study
MilestoneRegorafenib 160 mgPlacebo
Started1411
Participants received treatment1411
Completed10
Not completed1311
Withdrew: Ae not assoc. with disease recurrence11
Withdrew: Disease recurrence (radiological)13
Withdrew: Study stopped by sponsor57
Withdrew: Withdrawal by subject60

Outcome measures

PrimaryDisease Free Survival (DFS) as Assessed by the Investigator

Disease free survival was evaluated by CT / MRI scans as assessed by the investigator, which was defined as the time (in days) from date of randomization to date of first observed radiographic disease recurrence (RECIST 1.1 criteria for measurable and non-measurable disease) or death due to any cause, if death occurred before disease recurrence was documented. For subjects without documented disease recurrence or death at the time of analysis, the DFS time was censored at the date of the last evaluable CT / MRI scan.

Time frame:
From date of randomization to date of first observed radiographic disease recurrence (RECIST 1.1 criteria for measurable and non-measurable disease) or death due to any cause, if death occurred before disease recurrence was documented.

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time (days) from randomization to death due to any cause. The OS time for subjects alive at the time of analysis was censored at their last date known to be alive.

Time frame:
Subjects who experienced disease recurrence (either during treatment or during Active Follow-up), or otherwise withdrew from the study for any reason other than death, were followed for overall survival unless consent was withdrawn.

No measurements were reported for this outcome.

Adverse events

Collected over From the start of study drug administration until 30 days after the last study medication intake.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib 160 mg (BAY73-4506)—2/14 (14.3%)13/14 (92.9%)
Placebo—0/11 (0%)10/11 (90.9%)
Most frequent serious events
Most frequent serious events
EventRegorafenib 160 mg (BAY73-4506)Placebo
Erythema multiformeSkin and subcutaneous tissue disorders1/140/11
Generalised erythemaSkin and subcutaneous tissue disorders1/140/11
Most frequent other events
Showing 10 of 101
Most frequent other events
EventRegorafenib 160 mg (BAY73-4506)Placebo
HypertensionVascular disorders7/141/11
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders6/141/11
Blood bilirubin increasedInvestigations5/140/11
DysphoniaRespiratory, thoracic and mediastinal disorders5/141/11
Aspartate aminotransferase increasedInvestigations4/140/11
AstheniaGeneral disorders4/142/11
ConstipationGastrointestinal disorders4/142/11
Lipase increasedInvestigations4/141/11
Platelet count decreasedInvestigations4/140/11
DiarrhoeaGastrointestinal disorders1/143/11

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Regorafenib 160 mgPlaceboTotal
Mean59.7 ± 11.2257.0 ± 9.8358.5 ± 10.50
Sex: Female, Male
Sex: Female, Male(Participants)Regorafenib 160 mgPlaceboTotal
Female9514
Male5611
08

Study locations

121 sites
  • Laguna Hills, California 92653, United States
  • Los Angeles, California 90033, United States
  • Los Angeles, California 90089, United States
  • Los Angeles, California 90095, United States
  • New Haven, Connecticut 06520-8064, United States
  • New Orleans, Louisiana 70121, United States
  • Baltimore, Maryland 21201-1595, United States
  • Detroit, Michigan 48202, United States
  • Rochester, Minnesota 55905, United States
  • Omaha, Nebraska 68106, United States
  • New Brunswick, New Jersey 08903-2681, United States
  • Buffalo, New York 14263-0001, United States
  • New York, New York 10021, United States
  • Syracuse, New York 13210, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Chattanooga, Tennessee 37421, United States
  • Germantown, Tennessee 38138, United States
  • Dallas, Texas 75390, United States
  • Richmond, Virginia 23298-0037, United States
  • Kirkland, Washington 98034, United States
  • Seattle, Washington 98101, United States
  • Seattle, Washington 98109, United States
  • Liverpool, New South Wales 2170, Australia
  • East Melbourne, Victoria 3002, Australia
  • Bentleigh East, 3165, Australia
  • Malvern, 3144, Australia
  • Edegem, 2650, Belgium
  • Leuven, 3000, Belgium
  • Liege, 4000, Belgium
  • Belo Horizonte, Minas Gerais 30110-090, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil
  • São José do Rio Preto, Sao Paulo, Brazil
  • São Paulo, Sao Paulo 01246-000, Brazil
  • Edmonton, Alberta T6G 1Z2, Canada
  • Toronto, Ontario M5G 1X8, Canada
  • Sherbrooke, Quebec J1H 5N4, Canada
  • Montreal, H2W 1S6, Canada
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Guangzhou, Guangdong 510060, China
  • Guangzhou, Guangdong 510655, China
  • Harbin, Heilongjiang, China
  • Wuhan, Hubei 430033, China
  • Changsha, Hunan 410008, China
  • Xi'an, Shaanxi 710032, China
  • Xi'an, Shaanxi 710038, China
  • Kunming, Yunnan 650118, China
  • Hangzhou, Zhejiang 310009, China
  • Hangzhou, Zhejiang 310016, China
  • Beijing, 100021, China
  • Beijing, 100071, China
  • Beijing, 100142, China
  • Beijing, 100730, China
  • Shanghai, 200030, China
  • Shanghai, 200032, China
  • Shanghai, 200127, China
  • Bordeaux, 33076, France
  • Brest, 29285, France
  • Clermont-Ferrand, 63000, France
  • LYON Cedex 08, 69373, France
  • Marseille, 13385, France
  • Paris, 75651, France
  • Poitiers Cedex, 86021, France
  • Tours, 37044, France
  • Villejuif, 94800, France
  • München, Bayern 81377, Germany
  • Frankfurt, Hessen 60590, Germany
  • Oldenburg, Niedersachsen 26133, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Berlin, 12200, Germany
  • Haifa, 3109601, Israel
  • Ramat Gan, 52482, Israel
  • Tel Aviv, 64239, Israel
  • Napoli, Campania 80131, Italy
  • Reggio Emilia, Emilia-Romagna 42123, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Roma, Lazio 00189, Italy
  • Brescia, Lombardia 25124, Italy
  • Milano, Lombardia 20089, Italy
  • Milano, Lombardia 20133, Italy
  • Milano, Lombardia 20141, Italy
  • Foggia, Puglia 71013, Italy
  • Firenze, Toscana 50134, Italy
  • Pisa, Toscana 56126, Italy
  • Kashiwa, Chiba 277-8577, Japan
  • Sapporo, Hokkaido 006-8555, Japan
  • Sapporo, Hokkaido 060-0004, Japan
  • Sapporo, Hokkaido 060-8648, Japan
  • Akashi, Hyogo 673-8558, Japan
  • Amagasaki, Hyogo 660-8511, Japan
  • Kobe, Hyogo 650-0047, Japan
  • Kasama, Ibaraki 309-1793, Japan
  • Yokohama, Kanagawa 241-8515, Japan
  • Suita, Osaka 565-0871, Japan
  • Takatsuki, Osaka 569-8686, Japan
  • Sunto, Shizuoka 411-8777, Japan
  • Shimotsuke, Tochigi 329-0498, Japan
  • Koto-ku, Tokyo 135-8550, Japan
  • Minato-ku, Tokyo 105-8471, Japan
  • Mitaka, Tokyo 181-8611, Japan

Showing the first 100 of 121 sites across 14 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in Aug 2016, 32 months.

Results were first posted in Oct 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2013
First posted
Sep 11, 2013
StartActual
Dec 2, 2013
Primary completionActual
Aug 29, 2016
CompletionActual
Aug 29, 2016
Results first posted
Oct 20, 2017
Last update
Oct 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01939223
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 11, 2013
Start date
Dec 2, 2013
Primary completion
Aug 29, 2016
Completion
Aug 29, 2016
Results posted
Oct 20, 2017
Last update
Oct 20, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion